PMC:7205724 / 2420-2958 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"98","span":{"begin":224,"end":232},"obj":"Species"},{"id":"99","span":{"begin":270,"end":278},"obj":"Species"},{"id":"100","span":{"begin":246,"end":265},"obj":"Chemical"},{"id":"101","span":{"begin":91,"end":99},"obj":"Disease"},{"id":"102","span":{"begin":173,"end":181},"obj":"Disease"},{"id":"103","span":{"begin":337,"end":342},"obj":"Disease"},{"id":"104","span":{"begin":455,"end":463},"obj":"Disease"},{"id":"105","span":{"begin":529,"end":537},"obj":"Disease"}],"attributes":[{"id":"A98","pred":"tao:has_database_id","subj":"98","obj":"Tax:9606"},{"id":"A99","pred":"tao:has_database_id","subj":"99","obj":"Tax:9606"},{"id":"A100","pred":"tao:has_database_id","subj":"100","obj":"MESH:C558899"},{"id":"A101","pred":"tao:has_database_id","subj":"101","obj":"MESH:C000657245"},{"id":"A102","pred":"tao:has_database_id","subj":"102","obj":"MESH:C000657245"},{"id":"A103","pred":"tao:has_database_id","subj":"103","obj":"MESH:D003643"},{"id":"A104","pred":"tao:has_database_id","subj":"104","obj":"MESH:C000657245"},{"id":"A105","pred":"tao:has_database_id","subj":"105","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Moreover, most of the best available anti-viral agents are not helpful in the treatment of COVID-19. A randomized controlled trial of 199 hospitalized adults with confirmed COVID-19 demonstrated no actual difference between patients who received lopinavir-ritonavir and patients who received standard care alone in clinical improvement, death rate, and positive virus test rate at day 28 [1]. Here we review intermediate indicators of the pathogenesis of COVID-19 that have the potential of being considered for the treatment of COVID-19."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T23","span":{"begin":91,"end":99},"obj":"Disease"},{"id":"T24","span":{"begin":173,"end":181},"obj":"Disease"},{"id":"T25","span":{"begin":455,"end":463},"obj":"Disease"},{"id":"T26","span":{"begin":529,"end":537},"obj":"Disease"}],"attributes":[{"id":"A23","pred":"mondo_id","subj":"T23","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A24","pred":"mondo_id","subj":"T24","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A25","pred":"mondo_id","subj":"T25","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A26","pred":"mondo_id","subj":"T26","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"Moreover, most of the best available anti-viral agents are not helpful in the treatment of COVID-19. A randomized controlled trial of 199 hospitalized adults with confirmed COVID-19 demonstrated no actual difference between patients who received lopinavir-ritonavir and patients who received standard care alone in clinical improvement, death rate, and positive virus test rate at day 28 [1]. Here we review intermediate indicators of the pathogenesis of COVID-19 that have the potential of being considered for the treatment of COVID-19."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T13","span":{"begin":101,"end":102},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T14","span":{"begin":362,"end":367},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T15","span":{"begin":368,"end":372},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"}],"text":"Moreover, most of the best available anti-viral agents are not helpful in the treatment of COVID-19. A randomized controlled trial of 199 hospitalized adults with confirmed COVID-19 demonstrated no actual difference between patients who received lopinavir-ritonavir and patients who received standard care alone in clinical improvement, death rate, and positive virus test rate at day 28 [1]. Here we review intermediate indicators of the pathogenesis of COVID-19 that have the potential of being considered for the treatment of COVID-19."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T9","span":{"begin":37,"end":54},"obj":"Chemical"},{"id":"T10","span":{"begin":246,"end":265},"obj":"Chemical"},{"id":"T11","span":{"begin":246,"end":255},"obj":"Chemical"},{"id":"T12","span":{"begin":256,"end":265},"obj":"Chemical"}],"attributes":[{"id":"A9","pred":"chebi_id","subj":"T9","obj":"http://purl.obolibrary.org/obo/CHEBI_22587"},{"id":"A10","pred":"chebi_id","subj":"T10","obj":"http://purl.obolibrary.org/obo/CHEBI_145924"},{"id":"A11","pred":"chebi_id","subj":"T11","obj":"http://purl.obolibrary.org/obo/CHEBI_31781"},{"id":"A12","pred":"chebi_id","subj":"T12","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"}],"text":"Moreover, most of the best available anti-viral agents are not helpful in the treatment of COVID-19. A randomized controlled trial of 199 hospitalized adults with confirmed COVID-19 demonstrated no actual difference between patients who received lopinavir-ritonavir and patients who received standard care alone in clinical improvement, death rate, and positive virus test rate at day 28 [1]. Here we review intermediate indicators of the pathogenesis of COVID-19 that have the potential of being considered for the treatment of COVID-19."}

{"project":"LitCovid-sample-PD-IDO","denotations":[{"id":"T4","span":{"begin":362,"end":367},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"}],"text":"Moreover, most of the best available anti-viral agents are not helpful in the treatment of COVID-19. A randomized controlled trial of 199 hospitalized adults with confirmed COVID-19 demonstrated no actual difference between patients who received lopinavir-ritonavir and patients who received standard care alone in clinical improvement, death rate, and positive virus test rate at day 28 [1]. Here we review intermediate indicators of the pathogenesis of COVID-19 that have the potential of being considered for the treatment of COVID-19."}

{"project":"LitCovid-sample-CHEBI","denotations":[{"id":"T8","span":{"begin":246,"end":265},"obj":"Chemical"}],"attributes":[{"id":"A8","pred":"chebi_id","subj":"T8","obj":"http://purl.obolibrary.org/obo/CHEBI_145924"}],"text":"Moreover, most of the best available anti-viral agents are not helpful in the treatment of COVID-19. A randomized controlled trial of 199 hospitalized adults with confirmed COVID-19 demonstrated no actual difference between patients who received lopinavir-ritonavir and patients who received standard care alone in clinical improvement, death rate, and positive virus test rate at day 28 [1]. Here we review intermediate indicators of the pathogenesis of COVID-19 that have the potential of being considered for the treatment of COVID-19."}

{"project":"LitCovid-sample-PD-NCBITaxon","denotations":[{"id":"T25","span":{"begin":91,"end":99},"obj":"Species"},{"id":"T26","span":{"begin":173,"end":181},"obj":"Species"},{"id":"T27","span":{"begin":421,"end":431},"obj":"Species"},{"id":"T28","span":{"begin":455,"end":463},"obj":"Species"},{"id":"T29","span":{"begin":529,"end":537},"obj":"Species"}],"attributes":[{"id":"A29","pred":"ncbi_taxonomy_id","subj":"T29","obj":"NCBItxid:2697049"},{"id":"A28","pred":"ncbi_taxonomy_id","subj":"T28","obj":"NCBItxid:2697049"},{"id":"A25","pred":"ncbi_taxonomy_id","subj":"T25","obj":"NCBItxid:2697049"},{"id":"A27","pred":"ncbi_taxonomy_id","subj":"T27","obj":"NCBItxid:189528"},{"id":"A26","pred":"ncbi_taxonomy_id","subj":"T26","obj":"NCBItxid:2697049"}],"namespaces":[{"prefix":"NCBItxid","uri":"http://purl.bioontology.org/ontology/NCBITAXON/"}],"text":"Moreover, most of the best available anti-viral agents are not helpful in the treatment of COVID-19. A randomized controlled trial of 199 hospitalized adults with confirmed COVID-19 demonstrated no actual difference between patients who received lopinavir-ritonavir and patients who received standard care alone in clinical improvement, death rate, and positive virus test rate at day 28 [1]. Here we review intermediate indicators of the pathogenesis of COVID-19 that have the potential of being considered for the treatment of COVID-19."}

{"project":"LitCovid-sample-sentences","denotations":[{"id":"T28","span":{"begin":393,"end":538},"obj":"Sentence"},{"id":"T26","span":{"begin":0,"end":100},"obj":"Sentence"},{"id":"T27","span":{"begin":101,"end":392},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Moreover, most of the best available anti-viral agents are not helpful in the treatment of COVID-19. A randomized controlled trial of 199 hospitalized adults with confirmed COVID-19 demonstrated no actual difference between patients who received lopinavir-ritonavir and patients who received standard care alone in clinical improvement, death rate, and positive virus test rate at day 28 [1]. Here we review intermediate indicators of the pathogenesis of COVID-19 that have the potential of being considered for the treatment of COVID-19."}

{"project":"LitCovid-sample-Pubtator","denotations":[{"id":"101","span":{"begin":91,"end":99},"obj":"Disease"},{"id":"102","span":{"begin":173,"end":181},"obj":"Disease"},{"id":"98","span":{"begin":224,"end":232},"obj":"Species"},{"id":"100","span":{"begin":246,"end":265},"obj":"Chemical"},{"id":"99","span":{"begin":270,"end":278},"obj":"Species"},{"id":"103","span":{"begin":337,"end":342},"obj":"Disease"},{"id":"104","span":{"begin":455,"end":463},"obj":"Disease"},{"id":"105","span":{"begin":529,"end":537},"obj":"Disease"}],"attributes":[{"id":"A101","pred":"pubann:denotes","subj":"101","obj":"MESH:C000657245"},{"id":"A99","pred":"pubann:denotes","subj":"99","obj":"Tax:9606"},{"id":"A102","pred":"pubann:denotes","subj":"102","obj":"MESH:C000657245"},{"id":"A98","pred":"pubann:denotes","subj":"98","obj":"Tax:9606"},{"id":"A100","pred":"pubann:denotes","subj":"100","obj":"MESH:C558899"},{"id":"A105","pred":"pubann:denotes","subj":"105","obj":"MESH:C000657245"},{"id":"A104","pred":"pubann:denotes","subj":"104","obj":"MESH:C000657245"},{"id":"A103","pred":"pubann:denotes","subj":"103","obj":"MESH:D003643"}],"text":"Moreover, most of the best available anti-viral agents are not helpful in the treatment of COVID-19. A randomized controlled trial of 199 hospitalized adults with confirmed COVID-19 demonstrated no actual difference between patients who received lopinavir-ritonavir and patients who received standard care alone in clinical improvement, death rate, and positive virus test rate at day 28 [1]. Here we review intermediate indicators of the pathogenesis of COVID-19 that have the potential of being considered for the treatment of COVID-19."}

{"project":"LitCovid-sample-Enju","denotations":[{"id":"T377","span":{"begin":0,"end":8},"obj":"RB"},{"id":"T378","span":{"begin":8,"end":9},"obj":"-COMMA-"},{"id":"T379","span":{"begin":10,"end":14},"obj":"JJS"},{"id":"T380","span":{"begin":15,"end":17},"obj":"IN"},{"id":"T381","span":{"begin":18,"end":21},"obj":"DT"},{"id":"T382","span":{"begin":22,"end":26},"obj":"JJS"},{"id":"T383","span":{"begin":27,"end":36},"obj":"JJ"},{"id":"T384","span":{"begin":37,"end":47},"obj":"JJ"},{"id":"T385","span":{"begin":48,"end":54},"obj":"NNS"},{"id":"T386","span":{"begin":55,"end":58},"obj":"VBP"},{"id":"T387","span":{"begin":59,"end":62},"obj":"RB"},{"id":"T388","span":{"begin":63,"end":70},"obj":"JJ"},{"id":"T389","span":{"begin":71,"end":73},"obj":"IN"},{"id":"T390","span":{"begin":74,"end":77},"obj":"DT"},{"id":"T391","span":{"begin":78,"end":87},"obj":"NN"},{"id":"T392","span":{"begin":88,"end":90},"obj":"IN"},{"id":"T393","span":{"begin":91,"end":99},"obj":"NN"},{"id":"T394","span":{"begin":101,"end":102},"obj":"DT"},{"id":"T395","span":{"begin":103,"end":113},"obj":"VBN"},{"id":"T396","span":{"begin":114,"end":124},"obj":"VBN"},{"id":"T397","span":{"begin":125,"end":130},"obj":"NN"},{"id":"T398","span":{"begin":131,"end":133},"obj":"IN"},{"id":"T399","span":{"begin":134,"end":137},"obj":"CD"},{"id":"T400","span":{"begin":138,"end":150},"obj":"VBN"},{"id":"T401","span":{"begin":151,"end":157},"obj":"NNS"},{"id":"T402","span":{"begin":158,"end":162},"obj":"IN"},{"id":"T403","span":{"begin":163,"end":172},"obj":"VBN"},{"id":"T404","span":{"begin":173,"end":181},"obj":"NN"},{"id":"T405","span":{"begin":182,"end":194},"obj":"VBD"},{"id":"T406","span":{"begin":195,"end":197},"obj":"DT"},{"id":"T407","span":{"begin":198,"end":204},"obj":"JJ"},{"id":"T408","span":{"begin":205,"end":215},"obj":"NN"},{"id":"T409","span":{"begin":216,"end":223},"obj":"IN"},{"id":"T410","span":{"begin":224,"end":232},"obj":"NNS"},{"id":"T411","span":{"begin":233,"end":236},"obj":"WP"},{"id":"T412","span":{"begin":237,"end":245},"obj":"VBD"},{"id":"T413","span":{"begin":246,"end":265},"obj":"NN"},{"id":"T414","span":{"begin":266,"end":269},"obj":"CC"},{"id":"T415","span":{"begin":270,"end":278},"obj":"NNS"},{"id":"T416","span":{"begin":279,"end":282},"obj":"WP"},{"id":"T417","span":{"begin":283,"end":291},"obj":"VBD"},{"id":"T418","span":{"begin":292,"end":300},"obj":"JJ"},{"id":"T419","span":{"begin":301,"end":305},"obj":"NN"},{"id":"T420","span":{"begin":306,"end":311},"obj":"RB"},{"id":"T421","span":{"begin":312,"end":314},"obj":"IN"},{"id":"T422","span":{"begin":315,"end":323},"obj":"JJ"},{"id":"T423","span":{"begin":324,"end":335},"obj":"NN"},{"id":"T424","span":{"begin":335,"end":336},"obj":"-COMMA-"},{"id":"T425","span":{"begin":337,"end":342},"obj":"NN"},{"id":"T426","span":{"begin":343,"end":347},"obj":"NN"},{"id":"T427","span":{"begin":347,"end":348},"obj":"-COMMA-"},{"id":"T428","span":{"begin":349,"end":352},"obj":"CC"},{"id":"T429","span":{"begin":353,"end":361},"obj":"JJ"},{"id":"T430","span":{"begin":362,"end":367},"obj":"NN"},{"id":"T431","span":{"begin":368,"end":372},"obj":"NN"},{"id":"T432","span":{"begin":373,"end":377},"obj":"NN"},{"id":"T433","span":{"begin":378,"end":380},"obj":"IN"},{"id":"T434","span":{"begin":381,"end":384},"obj":"NN"},{"id":"T435","span":{"begin":385,"end":387},"obj":"CD"},{"id":"T436","span":{"begin":388,"end":389},"obj":"-LRB-"},{"id":"T437","span":{"begin":389,"end":390},"obj":"CD"},{"id":"T438","span":{"begin":390,"end":391},"obj":"-RRB-"},{"id":"T439","span":{"begin":393,"end":397},"obj":"RB"},{"id":"T440","span":{"begin":398,"end":400},"obj":"PRP"},{"id":"T441","span":{"begin":401,"end":407},"obj":"VBP"},{"id":"T442","span":{"begin":408,"end":420},"obj":"JJ"},{"id":"T443","span":{"begin":421,"end":431},"obj":"NNS"},{"id":"T444","span":{"begin":432,"end":434},"obj":"IN"},{"id":"T445","span":{"begin":435,"end":438},"obj":"DT"},{"id":"T446","span":{"begin":439,"end":451},"obj":"NN"},{"id":"T447","span":{"begin":452,"end":454},"obj":"IN"},{"id":"T448","span":{"begin":455,"end":463},"obj":"NN"},{"id":"T449","span":{"begin":464,"end":468},"obj":"WDT"},{"id":"T450","span":{"begin":469,"end":473},"obj":"VBP"},{"id":"T451","span":{"begin":474,"end":477},"obj":"DT"},{"id":"T452","span":{"begin":478,"end":487},"obj":"NN"},{"id":"T453","span":{"begin":488,"end":490},"obj":"IN"},{"id":"T454","span":{"begin":491,"end":496},"obj":"VBG"},{"id":"T455","span":{"begin":497,"end":507},"obj":"VBN"},{"id":"T456","span":{"begin":508,"end":511},"obj":"IN"},{"id":"T457","span":{"begin":512,"end":515},"obj":"DT"},{"id":"T458","span":{"begin":516,"end":525},"obj":"NN"},{"id":"T459","span":{"begin":526,"end":528},"obj":"IN"},{"id":"T460","span":{"begin":529,"end":537},"obj":"NN"}],"relations":[{"id":"R454","pred":"arg2Of","subj":"T458","obj":"T456"},{"id":"R455","pred":"arg1Of","subj":"T458","obj":"T457"},{"id":"R456","pred":"arg1Of","subj":"T458","obj":"T459"},{"id":"R457","pred":"arg2Of","subj":"T460","obj":"T459"},{"id":"R376","pred":"arg1Of","subj":"T386","obj":"T377"},{"id":"R377","pred":"arg1Of","subj":"T386","obj":"T378"},{"id":"R378","pred":"arg1Of","subj":"T379","obj":"T380"},{"id":"R379","pred":"arg2Of","subj":"T385","obj":"T380"},{"id":"R380","pred":"arg1Of","subj":"T385","obj":"T381"},{"id":"R381","pred":"arg1Of","subj":"T383","obj":"T382"},{"id":"R382","pred":"arg1Of","subj":"T385","obj":"T383"},{"id":"R383","pred":"arg1Of","subj":"T385","obj":"T384"},{"id":"R384","pred":"arg1Of","subj":"T379","obj":"T386"},{"id":"R385","pred":"arg2Of","subj":"T388","obj":"T386"},{"id":"R386","pred":"arg1Of","subj":"T386","obj":"T387"},{"id":"R387","pred":"arg1Of","subj":"T379","obj":"T388"},{"id":"R388","pred":"arg1Of","subj":"T386","obj":"T389"},{"id":"R389","pred":"arg2Of","subj":"T391","obj":"T389"},{"id":"R390","pred":"arg1Of","subj":"T391","obj":"T390"},{"id":"R391","pred":"arg1Of","subj":"T391","obj":"T392"},{"id":"R392","pred":"arg2Of","subj":"T393","obj":"T392"},{"id":"R393","pred":"arg1Of","subj":"T397","obj":"T394"},{"id":"R394","pred":"arg2Of","subj":"T397","obj":"T395"},{"id":"R395","pred":"arg2Of","subj":"T397","obj":"T396"},{"id":"R396","pred":"arg1Of","subj":"T397","obj":"T398"},{"id":"R397","pred":"arg2Of","subj":"T401","obj":"T398"},{"id":"R398","pred":"arg1Of","subj":"T401","obj":"T399"},{"id":"R399","pred":"arg2Of","subj":"T401","obj":"T400"},{"id":"R400","pred":"arg1Of","subj":"T401","obj":"T402"},{"id":"R401","pred":"arg2Of","subj":"T404","obj":"T402"},{"id":"R402","pred":"arg2Of","subj":"T404","obj":"T403"},{"id":"R403","pred":"arg1Of","subj":"T397","obj":"T405"},{"id":"R404","pred":"arg2Of","subj":"T408","obj":"T405"},{"id":"R405","pred":"arg1Of","subj":"T408","obj":"T406"},{"id":"R406","pred":"arg1Of","subj":"T408","obj":"T407"},{"id":"R407","pred":"arg1Of","subj":"T408","obj":"T409"},{"id":"R408","pred":"arg2Of","subj":"T410","obj":"T409"},{"id":"R409","pred":"arg1Of","subj":"T410","obj":"T411"},{"id":"R410","pred":"arg1Of","subj":"T410","obj":"T412"},{"id":"R411","pred":"arg2Of","subj":"T414","obj":"T412"},{"id":"R412","pred":"arg1Of","subj":"T413","obj":"T414"},{"id":"R413","pred":"arg2Of","subj":"T415","obj":"T414"},{"id":"R414","pred":"arg1Of","subj":"T410","obj":"T416"},{"id":"R415","pred":"arg1Of","subj":"T410","obj":"T417"},{"id":"R416","pred":"arg2Of","subj":"T419","obj":"T417"},{"id":"R417","pred":"arg1Of","subj":"T419","obj":"T418"},{"id":"R418","pred":"arg1Of","subj":"T419","obj":"T420"},{"id":"R419","pred":"arg1Of","subj":"T417","obj":"T421"},{"id":"R420","pred":"arg2Of","subj":"T428","obj":"T421"},{"id":"R421","pred":"arg1Of","subj":"T423","obj":"T422"},{"id":"R422","pred":"arg1Of","subj":"T423","obj":"T424"},{"id":"R423","pred":"arg2Of","subj":"T426","obj":"T424"},{"id":"R424","pred":"arg1Of","subj":"T426","obj":"T425"},{"id":"R425","pred":"arg1Of","subj":"T428","obj":"T427"},{"id":"R426","pred":"arg1Of","subj":"T424","obj":"T428"},{"id":"R427","pred":"arg2Of","subj":"T432","obj":"T428"},{"id":"R428","pred":"arg1Of","subj":"T432","obj":"T429"},{"id":"R429","pred":"arg1Of","subj":"T432","obj":"T430"},{"id":"R430","pred":"arg1Of","subj":"T432","obj":"T431"},{"id":"R431","pred":"arg1Of","subj":"T432","obj":"T433"},{"id":"R432","pred":"arg2Of","subj":"T434","obj":"T433"},{"id":"R433","pred":"arg1Of","subj":"T434","obj":"T435"},{"id":"R434","pred":"arg1Of","subj":"T417","obj":"T436"},{"id":"R435","pred":"arg2Of","subj":"T437","obj":"T436"},{"id":"R436","pred":"arg3Of","subj":"T438","obj":"T436"},{"id":"R437","pred":"arg1Of","subj":"T441","obj":"T439"},{"id":"R438","pred":"arg1Of","subj":"T440","obj":"T441"},{"id":"R439","pred":"arg2Of","subj":"T443","obj":"T441"},{"id":"R440","pred":"arg1Of","subj":"T443","obj":"T442"},{"id":"R441","pred":"arg1Of","subj":"T443","obj":"T444"},{"id":"R442","pred":"arg2Of","subj":"T446","obj":"T444"},{"id":"R443","pred":"arg1Of","subj":"T446","obj":"T445"},{"id":"R444","pred":"arg1Of","subj":"T446","obj":"T447"},{"id":"R445","pred":"arg2Of","subj":"T448","obj":"T447"},{"id":"R446","pred":"arg1Of","subj":"T443","obj":"T449"},{"id":"R447","pred":"arg1Of","subj":"T443","obj":"T450"},{"id":"R448","pred":"arg2Of","subj":"T452","obj":"T450"},{"id":"R449","pred":"arg1Of","subj":"T452","obj":"T451"},{"id":"R450","pred":"arg1Of","subj":"T452","obj":"T453"},{"id":"R451","pred":"arg2Of","subj":"T455","obj":"T453"},{"id":"R452","pred":"arg2Of","subj":"T455","obj":"T454"},{"id":"R453","pred":"arg1Of","subj":"T455","obj":"T456"}],"text":"Moreover, most of the best available anti-viral agents are not helpful in the treatment of COVID-19. A randomized controlled trial of 199 hospitalized adults with confirmed COVID-19 demonstrated no actual difference between patients who received lopinavir-ritonavir and patients who received standard care alone in clinical improvement, death rate, and positive virus test rate at day 28 [1]. Here we review intermediate indicators of the pathogenesis of COVID-19 that have the potential of being considered for the treatment of COVID-19."}

{"project":"LitCovid-sample-PD-GO-BP-0","denotations":[{"id":"T3","span":{"begin":337,"end":342},"obj":"http://purl.obolibrary.org/obo/GO_0016265"},{"id":"T4","span":{"begin":439,"end":451},"obj":"http://purl.obolibrary.org/obo/GO_0009405"}],"text":"Moreover, most of the best available anti-viral agents are not helpful in the treatment of COVID-19. A randomized controlled trial of 199 hospitalized adults with confirmed COVID-19 demonstrated no actual difference between patients who received lopinavir-ritonavir and patients who received standard care alone in clinical improvement, death rate, and positive virus test rate at day 28 [1]. Here we review intermediate indicators of the pathogenesis of COVID-19 that have the potential of being considered for the treatment of COVID-19."}

{"project":"LitCovid-sample-PD-MONDO","denotations":[{"id":"T23","span":{"begin":91,"end":99},"obj":"Disease"},{"id":"T24","span":{"begin":173,"end":181},"obj":"Disease"},{"id":"T25","span":{"begin":455,"end":463},"obj":"Disease"},{"id":"T26","span":{"begin":529,"end":537},"obj":"Disease"}],"attributes":[{"id":"A24","pred":"mondo_id","subj":"T24","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A26","pred":"mondo_id","subj":"T26","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A23","pred":"mondo_id","subj":"T23","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A25","pred":"mondo_id","subj":"T25","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"Moreover, most of the best available anti-viral agents are not helpful in the treatment of COVID-19. A randomized controlled trial of 199 hospitalized adults with confirmed COVID-19 demonstrated no actual difference between patients who received lopinavir-ritonavir and patients who received standard care alone in clinical improvement, death rate, and positive virus test rate at day 28 [1]. Here we review intermediate indicators of the pathogenesis of COVID-19 that have the potential of being considered for the treatment of COVID-19."}

{"project":"LitCovid-sample-GO-BP","denotations":[{"id":"T2","span":{"begin":439,"end":451},"obj":"http://purl.obolibrary.org/obo/GO_0009405"}],"text":"Moreover, most of the best available anti-viral agents are not helpful in the treatment of COVID-19. A randomized controlled trial of 199 hospitalized adults with confirmed COVID-19 demonstrated no actual difference between patients who received lopinavir-ritonavir and patients who received standard care alone in clinical improvement, death rate, and positive virus test rate at day 28 [1]. Here we review intermediate indicators of the pathogenesis of COVID-19 that have the potential of being considered for the treatment of COVID-19."}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T2","span":{"begin":439,"end":451},"obj":"http://purl.obolibrary.org/obo/GO_0009405"}],"text":"Moreover, most of the best available anti-viral agents are not helpful in the treatment of COVID-19. A randomized controlled trial of 199 hospitalized adults with confirmed COVID-19 demonstrated no actual difference between patients who received lopinavir-ritonavir and patients who received standard care alone in clinical improvement, death rate, and positive virus test rate at day 28 [1]. Here we review intermediate indicators of the pathogenesis of COVID-19 that have the potential of being considered for the treatment of COVID-19."}

{"project":"LitCovid-sentences","denotations":[{"id":"T26","span":{"begin":0,"end":100},"obj":"Sentence"},{"id":"T27","span":{"begin":101,"end":392},"obj":"Sentence"},{"id":"T28","span":{"begin":393,"end":538},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Moreover, most of the best available anti-viral agents are not helpful in the treatment of COVID-19. A randomized controlled trial of 199 hospitalized adults with confirmed COVID-19 demonstrated no actual difference between patients who received lopinavir-ritonavir and patients who received standard care alone in clinical improvement, death rate, and positive virus test rate at day 28 [1]. Here we review intermediate indicators of the pathogenesis of COVID-19 that have the potential of being considered for the treatment of COVID-19."}